

**Thurrock Medicines Management & Safety Group**  
**22 July 2016**  
**The Thames Room, Civic Offices**

<b>Present:</b>	Dr P Martin (DP) Chair	GP Board Member
	Mr Jonathan Andrews (JA)	Deputy Head and Implementation Lead
	Ms Jane Richards (JR)	Lead nurse, TCCG
	Ms Helen Farrugia (HF)	Finance, TCCG
	Ms Lynne Hilkene (Minutes)	Administrator, TCCG
<b>Apologies</b>	Ms Françoise Price (FP)	Interim Head of Medicines Optimisation Team
	Ms Marie McIlwain (MM)	Senior Clinical and Implementation Pharmacist
	Ms Linda Smart (LS)	Deputy Chief Nurse

<b>1.</b>	<b>Welcome/Apologies and declarations of interest</b>
	As above. No declaration of interest.
<b>2.</b>	<b>Minutes of the meeting held on 20th May 2016</b>
	The Minutes of the previous meeting were approved.
<b>3.</b>	<b>Action Log</b>
	<ul style="list-style-type: none"> <li>1) The policy statements were agreed. It was noted these will shortly be available be on the website.</li> <li>2) It was noted there were a lot of requests for silk garments from Basildon Hospital. This has been raised with the MMC</li> <li>3) Diabetes Pathway – Dr Choo-Kang to write a pathway.</li> </ul>
<b>4.</b>	<b>Matters arising not on agenda</b>
	No matters arising from the minutes.
<b>5.</b>	<b>Finance Report and QIPP 15/16 and 16/17</b>
	JA gave over-view of the report. It was noted that the TCCG were starting to overtake the national prescribing growth. There were two drugs in particular to keep an eye on; Liothyronine Sodium and Rivaroxaban which had risen in cost. Discussion followed on growth in costs.
<b>6.</b>	<b>Practice Prescribing Budgets 15/16</b>
	No report to discuss. JA gave apologies – b/f next meeting.

7.	<p><b>Rebates for Consideration</b></p> <p>JA advised that two rebates had been signed up from Smith &amp; Nephew and Activa. The Chair asked whether a formulary had been agreed with NELFT. JA advised there was, but formulary compliance continued to be lower than expected.</p> <p>JR asked if practice nurses could be updated with the formulary on wound care. JR confirmed that she would arranged for Ray Norris to talk with the practice nurses. <b>ACTION: To update practice nurses on formulary for wound care.</b></p>
8.	<p><b>Policy Statements</b></p> <ul style="list-style-type: none"> <li>• <b>Fluoride policy</b> – JA advised that Dentists only should be prescribing these tooth pastes, and not GPs.</li> <li>• <b>Medical Devices</b> – JA confirmed the PAC recommendations that medical devices not included in the formulary should not be prescribed.</li> <li>• <b>PDE51s Policy</b> – JA advised that Generic Sildenafil was the only PDE5 inhibitor on the formulary. The Chair advised that the quantity prescribed on the NHS should read 4-8 tablets and NOT 4 tablets. <b>ACTION: Change Policy to read as above.</b></li> <li>• <b>Sunscreens</b> – JA confirmed that GPs should not be prescribing sunscreen preparations other than those with specific medical conditions.</li> <li>• <b>Travel Advice</b> – JA briefly ran through the policy.</li> <li>• <b>Hepatitis</b> – JA advised this was a single policy on the positional statement on Hep A &amp; B travel vaccines.</li> </ul>
9.	<p><b>PAC Update</b></p> <ul style="list-style-type: none"> <li>• 11 April 2016 – JA highlighted Sacubitril/Valsartan for heart failure.</li> <li>• 16 May 2016 – JA highlighted Insulin Toujeo. Consultant led at present.</li> <li>• Medicines Optimisation Patient Safety and Quality Committee Report – JA advised that under CCG responsibilities, the CCG should nominate a Controlled Drugs Responsible Officer.</li> </ul>
10.	<p><b>Addaction Patient Group Directions</b></p> <p>JA advised that Thurrock Council have asked the Medicines Management and Safety Group for agreement. There were no issues identified. <b>ACTION: JA to feedback to Addaction.</b></p>
11.	<p><b>A.O.B.</b></p> <ol style="list-style-type: none"> <li>1. It was noted that the Drug Safety Update was not on the Agenda. JA confirmed that MA had signed a Memorandum of Understanding regarding appointing a Controlled Drugs Responsible officer.</li> <li>2. NICE Guidelines – JA advised there had been three sets of guidelines received. JA highlighted the following: <ul style="list-style-type: none"> <li>• March 2016 - Guanfacine which was a prolonged release for ADHD.</li> <li>• April 2016 – Sucubitril/Varlsartan. Work in progress with Basildon hospital cardiologists. Expected update around September 2016.</li> <li>• April 2016 – Spiolto Respimat – New to the market.</li> <li>• May 2016 – Donepezil – now recommended for managing mild alzheimer’s disease.</li> </ul> </li> </ol> <p>May 2016 – Reversal: Idarucizumab – evidence summary.</p>
<p><b>Date of Next Meeting</b> 19 August 2016 at 2.30pm, Port Room, Thurrock CCG</p>	